Physician profile
Jonathan Kass
NPI 1700974441
$321.62
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2021: $15.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $70.17 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $59.98 | 2019 | |
| Pfizer INC. | $42.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.49 | 2019 | |
| Genentech USA, INC. | $32.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.61 | 2019 | |
| Erbe USA INC | $15.05 | 2021 | |
| Mylan Specialty L.P. | $14.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.52 | 2019 | |
| Genzyme Corporation | $14.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.